Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share

Incyte’s Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share

in Stocks

Reading Time: 2 mins read

Incyte Corporation’s (NASDAQ:INCY) Q2 adjusted EPS reached $0.99, compared to $1.01 posted a year ago. Analysts had estimated $0.87.

Q2 revenues increased by 25% Y/Y to $954.61 million, beating the consensus of $920.18 million.

Support authors and subscribe to content

This is premium stuff. Subscribe to read the entire article.

Gain access to all our Premium contents.
More than 100+ articles.

Subscribe Now

Unlock this article and gain permanent access to read it.

Unlock Now